

APPLIED GENETIC TECHNOLOGIES CORP

Form 8-K

July 18, 2017

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): July 17, 2017**

**APPLIED GENETIC TECHNOLOGIES CORPORATION**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-36370**  
**(Commission**

**File Number)**  
**14193 NW 119<sup>th</sup> Terrace**

**Suite 10**

**Alachua, Florida, 32165**

**(Address of principal executive offices) (Zip Code)**

**(386) 462-2204**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 17, 2017, the compensation committee of our board of directors approved bonus payments for fiscal year 2017 and salary changes for fiscal year 2018 for Susan Washer, our president and chief executive officer, Mark Shearman, our chief scientific officer, Stephen Potter, our vice president and chief business officer, Michael Goldstein, our chief medical officer and Jeffrey Chulay, our executive director of clinical strategy and former chief medical officer. The following table sets forth for each individual the amount of their bonus for fiscal year 2017 and their salary for fiscal year 2018.

<b>Name</b>	<b>Fiscal Year 2017 Bonus</b>	<b>Fiscal Year 2018 Salary</b>
Susan Washer	\$149,996.00	\$501,600.00
Mark Shearman	\$115,255.00	\$388,500.00
Stephen Potter	\$ 86,887.50	\$340,930.00
Michael Goldstein	\$ 54,390.00	\$381,100.00
Jeffrey Chulay	\$ 70,000.00	\$210,000.00

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**APPLIED GENETIC TECHNOLOGIES  
CORPORATION**

By: /s/ Lawrence E. Bullock  
Lawrence E. Bullock

Chief Financial Officer

Date: July 18, 2017